Related Experiment Video
Updated: Sep 2, 2025

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
Miller Fisher syndrome following COVID-19 vaccines: A scoping review
Jee-Eun Kim1, Byeol-A Yoon2,3, Yoo Hwan Kim4
1Department of Neurology, Ewha Womans University College of Medicine, Seoul, Korea.
Background And Purpose:
Miller Fisher syndrome (MFS), a variant of Guillain-Barré Syndrome (GBS), could be underestimated in evaluations of its adverse events (AEs) following COVID-19 vaccination. We aimed to identify and characterize MFS following COVID-19 vaccination.
Materials And Methods:
Relevant studies reported on during the COVID-19 pandemic were identified in the MEDLINE, Embase, and other databases.
Results:
Nine cases of MFS following COVID-19 vaccination from various regions were included. Unlike MFS following COVID-19 infection, patients with MFS following COVID-19 vaccination frequently presented with anti-GQ1b antibody positivity (44%, 4/9). Unlike GBS following COVID-19 vaccination, only two of nine (22%) cases of MFS following COVID-19 vaccination had developed after viral-vector-related vaccine administration.
Conclusions:
Miller Fisher syndrome following COVID-19 vaccination seems to have a different pathophysiology from MFS following COVID-19 infection and GBS following COVID-19 vaccination. This neurological syndrome with a rare incidence and difficulty in diagnosis should be considered an AE of COVID-19 vaccination.
Insights
Miller Fisher syndrome (MFS), a variant of Guillain-Barré Syndrome (GBS), is a rare adverse event following COVID-19 vaccination. This study identified MFS cases, noting distinct characteristics compared to MFS post-infection and GBS post-vaccination.
Area of Science:
- Neurology
- Immunology
- Vaccinology
Background:
- Miller Fisher syndrome (MFS) is a rare variant of Guillain-Barré Syndrome (GBS).
- Adverse events (AEs) following COVID-19 vaccination require thorough evaluation.
- MFS post-COVID-19 vaccination may be underestimated.
Purpose of the Study:
- To identify and characterize cases of MFS following COVID-19 vaccination.
- To compare MFS post-vaccination with MFS post-infection and GBS post-vaccination.
Main Methods:
- Systematic literature search of MEDLINE, Embase, and other databases.
- Inclusion of studies reporting MFS cases during the COVID-19 pandemic.
Main Results:
- Nine cases of MFS following COVID-19 vaccination were identified.
- Anti-GQ1b antibody positivity was frequent in MFS post-vaccination (44%).
- MFS post-vaccination was less commonly associated with viral-vector vaccines (22%) compared to GBS.
Conclusions:
- MFS following COVID-19 vaccination exhibits a different pathophysiology than MFS post-infection and GBS post-vaccination.
- MFS should be considered a potential AE of COVID-19 vaccination due to its rare incidence and diagnostic challenges.
Related Concept Videos
Vaccinations
Single Nucleotide Polymorphisms-SNPs

